Avidity Biosciences (RNA)

• Market cap: $5.83B
• 1 day: 1.25%
• 5 days: -5.81%
• 1 month: -8.81%
• 3 months: 38.34%
• 6 months: 33.07%
• Year to date: 30.08%
• 1 year: -9.12%
• 5 years: 18.22%
• 10 years: 42.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Employees: 391

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

147% more call options, than puts

Call options by funds: $10.4M | Put options by funds: $4.22M

16% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 73

1.84% more ownership

Funds ownership: 110.98% [Q1] → 112.82% (+1.84%) [Q2]

3% less capital invested

Capital invested by funds: $3.96B [Q1] → $3.86B (-$100M) [Q2]

6% less funds holding

Funds holding: 218 [Q1] → 206 (-12) [Q2]

22% less funds holding in top 10

Funds holding in top 10: 9 [Q1] → 7 (-2) [Q2]

27% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 37

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $55
• Avg. target: $71
• High target: $96

9 analyst ratings

• positive: 9 100%
• neutral: 0 0%
• negative: 0 0%

Roth Capital Boobalan Pachaiyappan	$62	Buy Initiated	17 Sep 2025
B of A Securities Geoff Meacham	$65	Buy Maintained	15 Sep 2025
HC Wainwright & Co. Ananda Ghosh	$87	Buy Maintained	12 Sep 2025
Needham Joseph Stringer	$65	Buy Maintained	10 Sep 2025
Chardan Capital Keay Nakae	$75	Buy Maintained	10 Sep 2025